Get notified when SPRB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Auditor added explicit going-concern uncertainty paragraph in 2025 audit opinion, citing substantial doubt about the Company's ability to continue operations despite $48.9M cash and $15M January 2026 debt proceeds.
Spruce delays TA-ERT filing to Q4 2026, cuts 62% of staff, raises $50M amid going concern
Filed March 9, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 15, 2025 · ~2 min read
Key Changes
-
high
BLA submission for lead asset TA-ERT delayed from H1 2026 to Q4 2026 due to FDA manufacturing requirements for two drug product qualification batches, pushing potential launch to mid-2027.
Business: TA-ERT BLA submission timing verify on EDGAR → -
high
TAMARIND Phase 2 trial discontinued in Q1 2026 after serious adverse event involving significant liver enzyme elevation, halting tildacerfont development in major depressive disorder.
Business: TAMARIND trial discontinuation verify on EDGAR → -
high
Workforce reduced 62% from 21 to 8 employees during 2025; company secured $50M private placement (October 2025) and $15M debt tranche (January 2026) but auditor flags substantial doubt about ability to continue as going concern.
Business: Employee headcount / MD&A: Going concern verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade SPRB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify